Zhengye Biotechnology Holding Ltd (ZYBT) Stock Analysis
Verdict: AVOID
Revenue contraction (-45% in 2 years) and crashing gross margins (8.3% TTM) render ZYBT's recent 50.4% surge a speculative micro-cap pump.
Investment score: 18/100
Analysis as of
Is Zhengye Biotechnology Holding Ltd stock worth reviewing? The TradeMates thesis
The TradeMates model assigns an AVOID rating to ZYBT due to collapsing top-line revenue, severe net losses, and extreme speculative volatility.
7-factor investment score
- Valuation: 15/100 (weight 20%)
- Financial Health: 10/100 (weight 15%)
- Technical Momentum: 30/100 (weight 15%)
- Earnings Quality: 10/100 (weight 15%)
- Insider Sentiment: 30/100 (weight 10%)
- Analyst Consensus: 20/100 (weight 10%)
- Risk-Adjusted Return: 15/100 (weight 15%)
Zhengye Biotechnology Holding Ltd opportunities and risks
What speaks for ZYBT
- Export expansion into international agricultural markets
What speaks against ZYBT
- Severe top-line contraction and margin collapse
Frequently asked questions about Zhengye Biotechnology Holding Ltd (ZYBT)
Is ZYBT stock a good investment?
The TradeMates model rates Zhengye Biotechnology Holding Ltd as AVOID with an investment score of 18/100. The TradeMates model assigns an AVOID rating to ZYBT due to collapsing top-line revenue, severe net losses, and extreme speculative volatility. This is algorithmic model output, not personal investment advice.
Is ZYBT stock a buy?
The TradeMates model verdict for ZYBT is AVOID with an investment score of 18/100. Treat this as a model signal to review, not a personal buy recommendation.